Therapeutic inhibition of the complement system

Pharmacological Reviews

Volumn 50, Issue 1, 1998, Pages 59-87

  Makrides, Savvas C ^a  

^a Praecis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCX 1470; C 089; CBP 2; CD59 ANTIGEN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLESTATIN; DECAY ACCELERATING FACTOR; DECORIN; DEXTRAN SULFATE; FIBROLASE; GLYCYRRHIZIC ACID; HEPARIN; HEPARIN DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; K 76; L 156602; LU 51198; M 5; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; NAFAMSTAT MESILATE; PEPTIDE DERIVATIVE; PR 226; PROTEOCHONDROITIN SULFATE; SESQUITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

BIOCHEMISTRY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR BIOLOGY; NONHUMAN; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; PEPTIDES; RECEPTORS, COMPLEMENT; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031919928     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (567)

1. Abbink JJ, Kamp AM, Nuijens JH, Erenberg AJ, Swaak AJ and Hack CE (1992) Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints. Ann Rheum Dm 51:1125-1128.
2. Adams EM, Brown MC, Nunge M, Krych M and Atkinson JP (1991) Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 147:3005-3011.
3. Ahearn JM and Fearon DT (1989) Structure and function of the complement receptors, CR1 (CD35), and CR2 (CD21). Adv Immunol 46:183-219.
4. Albelda SM, Smith CW and Ward PA (1994) Adhesion molecules and inflammatory injury FASEB J 8:504-512.
5. Allan J (1997) Silk purse or sow's ear. Nat Med 3:275-276.
6. Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng ZZ, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ and Kuraar C (1996) Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 271:20231-20234
7. Anderson DJ, Abbott AF and Jack RM (1993) The role of complement component C3b and its receptors in sperm-oocyte interaction. Proc Natl Acad Sci USA 90:10051-10055.
8. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S and Fujita M (1984) Pharmacological studies of FUT-175, nafamstat mesilate: Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35:203-227.
9. Arakawa K, Akami T, Okamoto M, Akioka K, Lee PC, Sugano Y, Kamei J, Suzuki T, Nagase H, Tsuchihashi Y and Oka T (1994) Prolongation of heart xenograft survival in the NK-deficienl rat. Transplant Proc 26:1266-1267.
10. Asghar SS (1984) Pharmacological manipulation of complement system Pharmacol Rev 36:223-244.
11. Asghar SS (1995) Membrane regulators of complement activation and their aberrant expression in disease. Lab Invest 72:254-271.
12. Auchincloss H Jr (1997) Xenotransplantation literature update. Xenotransplantation 4:7-74.
13. Ayesh SK, Azar Y, Barghouti II, Ruedi JM, Babior BM and Matzner Y (1995) Purification and characterization of a C5a-inactivating enzyme from human peritoneal fluid. Blood 85:3503-3509.
14. Bach FH, Fishman JA, Daniels N, Proimos J, Anderson B, Carpenter CB, Forrow L, Robson SC, and Fineberg HV (1998) Uncertainty in Xenotransplantation. Individual benefit versus collective risk. Nat Med 4:141-144.
15. Bach FH, Roboon SC, Winkler H, Perron C, Stuhlmeier KM, Wrighton CJ and Hancock WW (1995) Barriers to xenotransplantation Nat Med 1:869-873
16. Bach FH. Winkler H, Ferran C. Hancock WW and Robson SC (1996) Delayed xenograft rejection. Immunol Today 17:379-384.
17. Baldwin WM III, Pruitt SK, Brauer RB, Daha MR and Sanfilippo F (1995) Complement in organ transplantation: Contributions to inflammation, injury, and rejection. Transplantation 59:797-808.
18. Baranyi L, Campbell W, Ohshima K, Fujimoto S, Boros M and Okada H (1995) The antisence homology box: A new motif within proteins that encodes biologically active peptides. Nat Med 1:894-901
19. Baranyi L, Campbell W and Okada H (1996) Antisence homology boxes in C5a receptor and C5a anaphylatoxin: A new method for identification of potentially active peptides. J Immunol 157:4591-4601
20. Barnum SR (1995) Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 6:132-146
21. Basta M, Fries LF and Frank MM (1991) High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytea. Blood 77:376-380.
22. Becker EL (1972) Synthetic inhibitors of complement, in Inflammation: Mechanisms and Control (Lepow IH and Ward PA, eds) pp 281-299, Academic Press, New York.
23. Belmont KM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G and Abramson S (1986) Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 29:1085-1089.
24. Benzaquen LR, Nicholson-Weller A and Halperin JA (1994) Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179:985-992
25. Berrens L, de la Cuadra B and Gallego MT (1997) Complement inactivation by allergenic plant pollen extracts. Life Sci 60:1497-1503.
26. x. Mol Biol Cell 7(suppl.):Abstract 449
27. Bertozzi CR (1995) Cracking the carbohydrate code for selectin recognition. Chemistry and Biology 2:703-708.
28. Bertozzi CR, Fukuda S and Rosen SD (1995) Sulfated disaccharide inhibitors of L-selectin: Deriving structural leads from a physiological selectin ligand. Biochem istry 34:14271-14278.
29. Blackmore TK, Sadlon TA, Ward HM, Lublin DM and Gordon DL (1996) Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol 157:5422-5427
30. Blakely ML, Van der Werf WJ, Berndt MC, Dalmasso AP, Bach FH and Hancock WW (1994) Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 58:1059-1066.
31. Blalock JE (1990) Complementarity of peptides specified by "sense" and "antisense" strands of DNA Trends Biotechnol 8:140-144.
32. Blalock JE (1995) Genetic origins of protein shape and interaction rules. Nat Med 1:876-878.
33. Blondin C, Fischer E, Boisson-Vidal C, Kazatchkine MD and Jozefonvicz J (1994) Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed. Mol Immunol 31:247-253.
34. Boackle RJ, Johnson BJ and Caughman GB (1979) An IgG primary sequence exposure theory for complement activation using synthetic peptides. Nature 282:742-743
35. Bokisch VA and Müller-Eberhard HJ (1970) Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. J Clin Invest 49:2427-2436.
36. Bokisch VA, Müller-Eberhard HJ and Cochrane CG (1969) Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 129:1109-1130.
37. Bordet J (1896) Sur le mode d'action des sérums préventifs. Ann Inst Pasteur 10:193-219.
38. Boulay F, Mery L, Tardif M, Brouchon L and Vignais P (1991) Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 30:2993-2999.
39. Brazelton TR and Morris RE (1996) Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 8:710-720.
40. Briggs JB, Larsen RA, Harris RB, Sekar KVS and Macher BA (1996) Structure/ activity studies of anti-inflammatory peptides based on a conserved peptide region of the lectin domain of E-, L- and P-selectin. Glycobiology 6:831-836.
41. Briggs JB, Oda Y, Gilbert JH, Schaefer ME and Macher BA (1995) Peptides inhibit selectin-mediated cell adhesion in vitro and neutrophil influx into inflammatory sites in vivo. Glycobiology 5:583-588
42. Brüggemann M and Neuberger MS (1996) Strategies for expressing human antibody repertoires in transgenic mice Immunol Today 17:391-397.
43. Brüggemann M and Taussig MJ (1997) Production of human antibody repertoires in transgenic mice. Curr Opin Biotechnol 8:455-458.
44. Buckel P (1996) Recombinant proteins for therapy. Trends Pharmacol Sci 17:450-456
45. Buerke M, Murohara T and Lefer AM (1995) Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91:393-402.
46. x-containing oligosaccharide attenuates myocardial reperfusion injury in cats. J Clin Inuest 93:1140-1148.
47. Butcher EC and Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272:60-66.
48. Byrne GW, McCurry KR, Martin MJ, McClellan SM, Platt JL and Logan JS (1997) Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63:149-155.
49. Cadman ED and Puttfarcken PS (1997) β-amyloid peptides initiate the complement cascade without producing a comparable effect on the terminal pathway in vitro. Exp Neurol 146:388-394.
50. Calne RY (1970) Organ transplantation between widely disparate species. Transplant Proc 2:550-556.
51. Campbell RD. Law SK, Reid KB and Sim RB (1988) Structure, organization, and regulation of the complement genes Annu Rev Immunol 6:161-195.
52. Candinas D, Lesnikoski B-A, Robson SC, Miyatake T, Scesney SM, Marsh HC, Ryan US, Dalmasso AP, Hancock WW and Bach FH (1996) Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation 62:336-342.
53. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, Broder S and Smith DH (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525-531.
54. Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW Jr. and Nussenzweig V (1987) Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins Nature 325:545-549.
55. Carroll MC, Alicot EM, Katzman PJ, Klickstein LB, Smith JA and Fearon DT(1988) Organization of the genes encoding complement receptors type 1 and 2, decayaccelerating factor and C4-binding protein in the RCA locus on human chromosome 1. J Exp Med 167:1271-1280.
56. Carroll MC and Fischer MB (1997) Complement and the immune response. Curr Opin Immunol 9:64-69.
57. Catterall CF, Lyons A, Sim RB, Day AJ and Harris TJ (1987) Characterization of primary amino acid sequence of human complement control protein factor I from an analysis of cDNA clones. Biochem J 242:849 -856.
58. Cecconi O, Nelson RM, Roberts WG, Hanasaki K, Mannori G, Schultz C, Ulich TR, Aruffo A and Bevilacqua MP (1994) Inositol polyanions: Noncarbohydrate inhibitors of L- and P-selectin that block inflammation. J Biol Chem 269:15060-15066.
59. Chapman LE and Fishman JA (1997) Xenotransplantation and infectious diseases, in Xenotransplantation: The Transplantation of Organs and Tissues Between Species (Cooper DKC, Kemp E, Platt JL and White DJG, eds) 2nd ed, pp 736-748, Springer, Berlin.
60. Chapman LE, Folks TM, Salomon DR, Patterson AP, Eggerman TE and Noguchi PD (1995) Xenotransplantation and xenogeneic infections. N Engl J Med 333:1498-1501.
61. Charreau B, Blondin C, Boisson-Vidal C, Soulillou J-P and Anegon I (1997) Efficiency of fucans in protecting porcine endothelial cells against complement activation and lysis by human serum. Transplant Proc 29:889-890.
62. Chávez-Cartaya R, Cozzi E, Pino-DeSola G, Jamieson NV and White DJ (1995) Regulation of complement activation in rat liver ischemia and reperfusion: Expression of endothelial CD59 (RIP). Transplant Proc 27:2852-2854.
63. Chen S, Frederickson RC and Brunden KR (1996) Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: Complement activation and therapeutic approaches. Neurobiol Aging 17:781-787.
64. Chen T and Rael ED (1997) Purification of M5, a fibrinolytic proteinase from Crotalus molossus molossus venom that attacks complement. Int J Biochem Cell Biol 29:789-799.
65. Chen Z, Cobbold S, Metcalfe S and Waldmann H (1992) Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. EurJ Immunol 22:805-810.
66. Chenoweth DE (1986) Complement mediators of inflammation, in Immunobiology (Ross G, ed) pp 63-86, Academic Press, New York.
67. Cheung AK, Parker CJ and Hohnholt M (1994) Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 46:1680-1687.
68. Cho SW, Oglesby TJ, Hsi BL, Adams EM and Atkinson JP (1991) Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay. Clin Exp Immunol 88:257-261.
69. Cboi NH, Mazda T and Tomita M (1989) A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Mol Immunol 26:35-840.
70. Christiansen D, Milland J, Thorley BR, McKenzie IFC and Loveland BE (1996) A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro Eur J Immunol 26:578-585.
71. Chung LP, Bentley DR and Reid KB (1985) Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J 230:133-141.
72. Co MS and Queen C (1991) Humanized antibodies for therapy. Nature 351:501-502.
73. Coehrane CG, Müller-Eberhard HJ and Aikin BS (1970) Depletion of plasma complement in vivo by a protein of cobra venom factor Its effect on various immunologic reactions. J Immunol 105:55-69.
74. Cole LB, Chu MM, Kilpatrick JM, Volanakis JE, Narayana SVL and Babu YS (1997) Structure of diisopropyl fluorophosphate-inhibited factor D. Acta Crystallogr D53: 143-150.
75. Cooper DKC, Kemp E, Platt JL and White DJG (1997) Xenotransplantation: The Transplantation of Organs and Tissues Between Species. 2nd ed. Springer, Berlin.
76. Couser WG (1993) Pathogenesis of giomerulonephritis. Kidney Int 42 (Suppl.):S19-826.
77. Couser WG, Baker PJ and Adler S (1965) Complement and the direct mediation of immune gloamerular injury: A new perspective. Kidney Int 28:879-890.
78. Couser WG, Johnson HJ, Young BA, Yeh CG, Toth CA and Rudolph AR (1995) The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 5:1888-1894.
79. Coyne KE, Hall SE, Thompson ES, Arce MA, Kinoshita T, Fujita T, Anstee DJ, Roase W and Lublin DM (1992) Mapping of epitopes, glycosylation sites and complement regulatory domains in human decay accelerating factor. J Immunol 149:2906-2913.
80. Cozzi E and White DJG (1995) The generation of transgenic pigs as potential organ donors for humans. Nat Med 1:964-966.
81. Craddock PR, Fehr J, Dalmasso AP, Brighan KL and Jacob HS (1977) Hemodialysis leukopenia: Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59:879-888.
82. Crass T, Raffetseder U, Martin U, Grove M, Klos A, Kohl J and Bautsch W (1996) Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Ear J Immunol 26:1944-1950.
83. Cui L, Carney DF and Hugli TE (1994) Primary structure and functional characterization of rat C5a: An anaphylatoxin with unusually high potency. Protein Sci 3:1169-1177.
84. Daha MR, Austen KF and Fearon DT (1977) The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function. J Immunol 119:812-817.
85. Dalmasso AP (1986) Complement in the pathophysiology and diagnosis of human diseases. Crit Rev Clin Lab Sci 24:123-183.
86. Dalmasso AP (1997) Role of complement in xenograft rejection, in Xenotransplantation: The Transplantation of Organs and Tissues Between Species (Cooper DKC, Kemp E, Platt JL and White DJG, eds) 2nd ed, pp 38-60, Springer, Berlin.
87. Dalmasso AP and Platt JL (1993) Prevention of complement-mediated activation of xenogeneic endothelial cells in an m vitro model of xenograft hyperacute rejection by C1 inhibitor Transplantation 86:1171-1176.
88. Dalmasso AP and Platt JL (1994) Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection. Transplant Proc 26:1246-1247.
89. Dalmasso AP, Vercellotti GM, Platt JL and Bach FH (1991) Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor: Potential for prevention of xenograft hyperacute rejection. Transplantation 52:530-533.
90. Davies A and Lachmann PJ (1993) Membrane defence against complement lysis. The structure and biological properties of CD59. Immunol Res 12:258-275.
91. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ and Waldmann H (1989) CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170:637-654.
92. Davis CF, Moore FD Jr, Rodrick ML, Fearon DT and Mannick JA (1987) Neutrophil activation after burn injury: Contributions of the classic complement pathway and of endotoxin. Surgery 102:477-484.
93. Davis AE III (1988) C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 6:595-628.
94. Davis AE III, Aulak KS, Zahedi K, Bissler JJ and Harrison RA (1993) C1 inhibitor. Methods Enzymol 223:97-120.
95. Davitz MA, Low MG and Nussenzweig V (1986) Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). J Exp Med 163:1150-1161.
96. D'Cruz OJ, Haas GG Jr. and Lambert H (1990) Evaluation of antisperm complement-dependent immune mediators in human ovarian follicular fluid. J Immunol 144:3841-384.
97. D'Cruz OJ, Haas GG Jr., Wang BL and DeBault LE (1991) Activation of human complement by IgG antisperm antibody and the demonstration of C3 and C5b-9-mediated immune injury to human sperm. J Immunol 146:611-620.
98. Dellinger RP, Zimmerman JL, Straube RC, Metzler MH, Wall M, Brown BK, Levin JL, Toth CA and Ryan US (1996) Results of a phase I trial of soluble complement receptor type 1 (TP10) in acute lung injury (ALI). Crit Care Med 24 (Suppl. 2):A29.
99. Dellinger RP, Zimmerman J, Metzler MH, Wall MJ, Brown BK, Straube R, Levin J and Ryan US (1995) Phase I trial of soluble complement receptor I (sCR1, TP10) in acute lung injury. Chest 106 (Suppl.):R.
100. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC and Fearon DT (1996) C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 271:346-350.
101. Deng S, Pascual M, Lou J, Buhler L, Wessel HP, Grau G, Schifferli JA and Morel P (1996) New synthetic sulfated oligosaccharides prolong survival of cardiac xenografts by inhibiting release of heparan sulfate from endothelial cells. Transplantation 61:1300-1305
102. Dennert G (1974) Effector mechanisms of cell-mediated immunity to xenogeneic cell antigens. J Immunol 113:201-208
103. Diamond LE, McCurry KR, Martin MJ, McClellan SB, Oldham ER, Platt JL and Logan JS (1996) Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 61:1241-1249.
104. x from a phage display library. J Immunol 157:732-738.
105. Doerschuk CM, Beyers N, Coxson HO, Wiggs B and Hogg JC (1993) Comparison of neutrophil and capillary diameters and their relation to neutrophil sequestration in the lung. J Appl Physiol 74:3040-3045.
106. Doerschuk CM, Quinlan WM, Doyle NA, Bullard DC, Vestweber D, Jones ML, Takei F, Ward PA and Beaudet AL (1996) The role of P-selectin and ICAM-1 in acute lung injury as determined using blocking antibodies and mutant mice. J Immunol 157:4609-4614
107. Dorig RE, Marcil A, Chopra A and Richardson CD (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75:295-305.
108. Earis JE, Marcuson EC and Bernstein A (1985) Complement activation after myocardial infarction. Chest 87:186-190.
109. Ecker EE and Gross P (1929) Anticomplementary power of heparin. J Infect Dis 44:250-253.
110. Eikelenboom P, Zhan S-S, Van Gool WA and Allsop D (1994) Inflammatory mechanisms in Alzheimer'i disease. Trends Phamacol Sci 15:447-450
111. Englberger W, Hadding V, Etschenberg E, Graf E, Leyck S, Winkelmann J and Parnham MJ (1988) Rosmarinic acid: A new inhibitor of complement C3-convertase with anti-inflammatory activity. Int J Immunopharmacol 10:729-737.
112. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taytor AA and Smith CW (1991) Inflammation in the course of early myocardial ischemia. FASEB J 5:2529-2537
113. Eppinger MJ, Deeb GM, Bolling SF and Ward PA (1997) Mediators of ischemia-reperftuion injury of rat lung. Am J Pathol 150:1773-1784.
114. Evana MJ, Rollins SA, Wolff DW, Bother RP, Norin AJ, Therrien DM, Grijalva GA, Mueller JP, Nye SH, Squinto SP and Wilkins JA (1996) In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 32:1183-1195.
115. Farriers TC and Atkinson JP (1987) Separation of self from non-self in the complement system. Immunol Today 8:212-215.
116. Farries TC, Lachmann PJ and Harrison RA (1988) Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochem J 253:667-675.
117. Fasman GD and Gilbert WA (1990) The prediction of transmembrane protein sequences and their conformation: An evaluation. Trends Biochem Sci 15:89-92.
118. Fearon DT (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 76:5867-5871.
119. Fearon DT (1991) Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors. Clin Exp Immunol 86(Suppl. 1):43-46.
120. Fearon DT and Austen KF (1975) Properdin: Binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 142:856-863.
121. Fearon DT, Austen KF and Ruddy S (1974) Properdin factor D: Characterization of its active site and isolation of the precursor form. J Exp Med 139:355-366.
122. Fearon DT and Carter RH (1995) The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity. Annu Rev Immunol 13:127-149.
123. Fearon DT and Wong WW (1983) Complement ligand-receptor interactions that mediate biological responses Annu Rev Immunol 1:243-271
124. Ferguson PJ, Martin EN, Greene KL, Kuhn S, Cafiso DS, Addona G and Taylor RP (1995a) Antigen-based heteropolymers facilitate, via primate erythrocyte complement receptor type 1, rapid erythrocyte binding of an autoantibody and its clearance from the circulation in rhesus monkeys. J Immunol 155:339-347.
125. Ferguson PJ, Reist CJ, Martin EN, Johnson C, Greene KL, Kuhn S, Niebur J, Emlen W and Taylor RP (1995b) Antigen-based heteropolymers: A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis Rheum 38: 190-200.
126. Fernandez HN and Hugli TE (1978) Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin: Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a, J Bio/ Chem 253:6955-6964
127. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR and Lonberg N (1996) High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14:845-851.
128. x-containing carbohydrate reduces infarct size: Role of selectins in myocardial reperfusion injury. Am J Phystol 271:H2086-H2096
129. Fodor WL, Rollins SA, Guilmette ER, Setter E and Squinto SP (1995) A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. J Immunol 155:4135-4138.
130. Fodor WL, Williams BL, Matis LA, Madri JA, Rollins SA, Knight JW, Velander W and Squinto SP (1994) Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 91:11153-11157.
131. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM and Ward PA (1994) C5a-induced expression of P-selectin in endothelial cells J Clin Invest 94:1147-1155.
132. Forty J, Hasan R, Cary N, White DJG and Wallwork J (1992) Hyperacute rejection of rabbit hearts by human blood is mediated by the alternative pathway of complement. Transplant Proc 24:488-489.
133. Fox KA (1990) Thrombolysis: Adjuvant therapy and the role of complement. Eur Heart J 11(Suppl. F):36-42.
134. x oligosaccharide. J Cell Biol 117:895-902.
135. Frank MM (1987) Complement in the pathophysiology of human disease. N Engl J Med 316:1525-1529
136. Frank MM (1994) Complement system, in Samter's Immunological Diseases (Frank MM, Austen KF, Claman HN and Unanue ER, eds) 5th ed, vol 1, pp 331-352, Little, Brown, Boston.
137. Fryer JP, Blondin B, Stadler C, Ivancic D, Rattner U, Kaplan B, Kaufman D, Abecassis M, Stuart F and Anderson B (1997) Inhibition of human serum mediated lysis of porcine endothelial cells using a novel peptide which blocks C1Q binding to xenoantibody. Transplant Proc 29:883-883.
138. Fryer JP, Leventhal JR, Dalmasso AP, Chen S, Simone PA, Goswitz JJ, Reinsmoen NL and Matas AJ (1995) Beyond hyperacute rejection: Accelerated rejection in a discordant xenograft model by adoptive transfer of specific cell subsets. Trans plantation 59:171-176
139. Fryer JP, Leventhal JR, Dalmasso AP, Chen S, Simone PA, Jessurun J, Sun LH, Reinsmoen NL and Matas AJ (1994) Cellular rejection in discordant xenografts when hyperacute rejection is prevented: Analysis using adoptive and passive transfer. Transpl Immunol 2:87-93.
140. Fujii S and Aoyama T (1984) Complement inhibitors Drugs Future 9:849-856.
141. Fujii S and Hitomi Y (1981) New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 661:342-345.
142. Fujise K, Revelle BM, Stacy L, Madison EL, Yeh ETH, Willerson JT and Beck PJ (1997) A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent. Circulation 95:715-722.
143. Fujita T, Inoue T, Ogawa K, Iida K and Tamura N (1987) The mechanism of action of decay-accelerating factor (DAF): DAP inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 165:1221-1228.
144. Gallinaro R, Cheadle WG, Applegate K and Polk HC Jr.(1992) The role of the complement system in trauma and infection. Surg Gynecol Obstet 174:435-440.
145. Gancevici GG and Popescu C (1987a) Natural inhibitors of complement: Isolation of pokeweed complement inhibitor(s) by ion exchange. Arch Roum Pathol Exp Microbiol 46:47-56.
146. Gancevici GG and Popescu C (1987b) Natural inhibitors of complement: Inactivation of the complement cascade in vitro by vegetal spices (Ocimum basilicum, Artemisia dracunculus and Thymus vulgaris). Arch Roum Pathol Exp Microbiol 46:321-331.
147. Gao Q, Kiyohara H, Cyong J and Yamada H (1989) Chemical properties and anticomplementary activities of polysaccharide fractions from roots and leaves of Panax ginseng. Planta Med 55:9-12.
148. Gardinali M, Padalino P, Vesconi S, Calcagno A, Ciappellano S, Conciato L, Chiara O, Agostoni A and Nespoli A (1992) Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis: Correlation with seventy of disease. Arch Surg 127:1219-1224.
149. Gatenby PA (1991) The role of complement in the aetiopathogenesis of systemic lupus erythematosus. Autoimmunity 11:61-66.
150. Gautreau C, Kojima T, Woimant G, Cardogo J, Devillier P and Housam D (1995) Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection: An in vivo and in vitro evaluation. Transplantation 60:903-907.
151. Geng JG, Heavner GA and McEver RP (1992) Lectin domain peptides from selectins interact with both cell surface ligands and Ca2+ ions. J Biol Chem 267:19846-19853.
152. Georgieva P, Ivanovska N, Bankova V and Popov S (1997) Anticomplement activity of lysine complexes of propolis phenolic constituents and their synthetic analogs. Z Noturforsch 52C:60-64.
153. Gerard C and Gerard NP (1994) C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 12:775-808.
154. Gerard NP and Gerard C (1991) The chemotactic receptor for human C5a anaphylatoxin. Nature 349:614-617.
155. Ghebrehiwet B, Lim B-L, Peerschke EIB, Willis AC and Reid KBM (1994) Isolation, cDNA cloning and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. J Exp Med 179:1809-1821.
156. Gigli I, Fujita T and Nussenzweig V (1979) Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci USA 76:6596-6600.
157. x analogue does not reduce myocardial infarct size after ischemia and reperfusion in dogs. Circulation 94:542-546.
158. Gillinov AM, DeValeria PA, Winkelstein JA, Wilson I, Curtis WE, Shaw D, Yeh CG, Rudolph AH, Baumgartner WA, Herskowitz A and Cameron DE (1993) Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 55:619-624.
159. Goldberger G, Bruns GA, Rita M, Edge MD and Kwiatkowski DJ (1987) Human complement factor I: Analysis of cDNA-derived primary structure and assignment of iU gene to chromosome 4. J Biol Chem 262:10065-10071
160. Gonda R, Tomoda M, Shimizu N and Yamada H (1990) Structure and anticompleraentary activity of an acidic polysaccharide from the leaves of Malva sylvestris var. mauritania. Carbohydr Res 198:323-329.
161. González-Rubio C, Jiménez-Clavero MA, Fontán G and López-Trascasa M (1994) The inhibitory effect of factor J on the alternative complement pathway. J Biol Chem 269:26017-26024.
162. Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N and Lamontagne LR (1992) Identification of carbohydrate structures that bind human antiporcine antibodies: Implications for discordant xenografting in humans. Transplant Proc 24:559-562.
163. Gordon DL, Kaufman RM, Blackmore TK, Kwong J and Lublin DM (1995) Identification of complement regulatory domains in human factor H. J Immunol 155:348-356
164. Gralinski MR, Park JL, Ozeck MA, Wiater BC and Lucchesi BR (1997) LU 51198, a highly sulfated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused rabbit heart. J Pharmacol Exp Ther 282:554-560.
165. Gralinski MR, Wiater BC, Assenmacher AN and Lucchesi BR (1996) Selective inhibition of the alternative complement pathway by sCR1 (desLHR-A) protects the rabbit isolated heart from human complement-mediated damage Immunopharmacology 34:79-88.
166. Green PJ, Yuen C-T, Childs RA, Chai W, Miyasaka M, Lemoine R, Lubineau A, Smith B, Ueno H, Nicolaou KC and Feizi T (1995) Further studies of the binding specificity of the leukocyte adhesion molecule, L-selectin, towards sulphated oligosaccharides-suggestion of a link between the selectin- and the integrin-mediated lymphocyte adhesion systems Glycobiology 5:29-38.
167. Grindley JN and Ogden JE (1995) Forecasting the future for protein drugs. Scrip Mag November:53-56.
168. Guan EN, Burgess WH, Robinson SL, Goodman EB, McTigue KJ and Tenner AJ (1991) Phagocytic cell molecules that bind the collagen-like region of C1q: Involvement in the C1q-mediated enhancement of phagocytosis. J Biol Chem 266:20345-20355.
169. Guan E, Robinson SL, Goodman EB and Tenner AJ (1994) Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J Immunol 152:4005-4016.
170. Gyongyossy-Issa MI, McLeod E and Devine DV (1994) Complement activation in platelet concentrates is surface-dependent and modulated by the platelets. J Lab Clin Med 123:859-868.
171. Hack CE, Nuijens JH, Felt-Bersma RJ, Schreuder WO, Eerenberg-Belmer AJ, Paardekooper J, Bronsveld W and Thys LG (1989) Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 86:20-26.
172. Hagmann WK and Sindelar RD (1992) Potential therapeutic modifiers of the com- plement cascade, in Annual Reports in Medicinal Chemistry (Bristol JA, ed) vol 27. pp 199-208. Academic Press, New York.
173. Hammer C (1997) Evolution: Its complexity and impact on xenotransplantation, in enotransplantation: The transplantation of organs and tissues between species (Cooper DKC, Kemp E. Platt JL and White DJG, eds) 2nd ed., pp 716-735. Springer. Berlin
174. Hancock WW (1997) Beyond hyperacute rejection Strategies for development of pig-primate xenotransplantation. Kidney Int 51(Suppl. 58):S36-S40.
175. Hardig Y, Hillarp A and Dahlbäck B (1997) The amino-terminal module of the C4b-binding protein α-chain is crucial for C4b binding and factor I-cofactor function. Biochem J 323:469-475
176. Hartmann K, Henz BM, Krüger-Krasagakes S, Köhl J, Burger R, Guhl S, Haase I, Lippert U and Zuberbier T (1997) C3a and C5a stimulate chemotaxis of human mast cells Blood 89:2863-2870.
177. Hartung HP, Schwenke C, Bitter-Suermann D and Toyka KV (1987) Guillain-Barre syndrome: Activated complement components C3a and C5a in CSF. Neurology 37:1006-1009
178. Haslam PL, Townsend PJ and Branthwaite MA (1980) Complement activation during cardiopulmonary bypass. Anaesthesia 35:22-26.
179. Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A, Haviland JC, Parks WC, Perlmutter DH and Wetsel RA (1995) Cellular expression of the C5a anaphylatoxin receptor (C5aR): Demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 154:1861-1869.
180. Hayashi S, Nagasaka T, Koike C, Kobayashi T, Hamada H, Yokoyama I, Saito I and Takagi H (1997) Effect of antisense ribozyme to alpha(1,3)galactosyl transferase gene on the expression of GAL alpha(1,3)GAL epitope. Transplant Proc 29:893-893.
181. Hayman EG, Pierschbacher MD, Ohgren Y and Ruoslahti E (1983) Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci USA 80:4003-4007
182. Heavner GA, Falcone M, Kruszynski M, Epps L, Mervic M, Riexinger D and McEver RP (1993) Peptides from multiple regions of the lectin domain of P-selectin inhibiting neutrophil adhesion. Int J Pept Protein Res 42:484-489
183. Heckl-Östreicher B, Wosnik A and Kirschfink M (1996) Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, Cl inhibitor and soluble complement receptor type 1: Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation 62:1693-1696.
184. Hengster P, Linke R, Feichtinger J, Hechenleitner P, Mark W, Eberl T, Klima G, Huemer H, Daha M and Margreiter R (1996) Mechanisms of hyperacute rejection of discordant liver xenograft. Xenotransplantation 3:246-251
185. Hensens OD, Borris RP, Koupal LR, Caldwell CG, Currie SA, Haidri AA, Homnick CF, Honeycutt SS, Lindenmayer SM, Schwartz CD, Weissberger BA, Woodruff HB, Zink DL, Zitano L, Fieldhouse JM, Rollins T, Springer MS and Springer JP (1991) L-156,602, a C5a antagonist with a novel cyclic hexadepsipeptide structure from Streptomyces sp. MA6348: Fermentation, isolation and structure determination. J Antibiot 44:249-254
186. Hicke BJ, Watson SR, Koenig A, Lynott CK, Bargatze RF, Chang Y-F, Ringquist S, Moon-McDermott L, Jennings S, Fitzwatcr T, Han H-L, Varki N, Albinana I, Willis MC, Varki A and Parma D (1996) DNA aptamers block L-selectin function in vivo: Inhibition of human lymphocyte trafficking in SCID mice. J Clin Invest 98:2688-2692.
187. Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK and Yeh CG (1997) A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J Immunol 158:2872-2881.
188. Hill JH and Ward PA (1971) The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133:885-900.
189. Hill J, Lindsay TF, Ortiz F, Ych CG, Hechtman HB and Moore Jr FD (1992) Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 149:1723-1728.
190. Hillarp A and Dahlbäck B ( 1990) Cloning of cDNA coding for the beta chain of human complement component C4b-binding protein: Sequence homology with the alpha chain Proc Natl Acad Sci USA 87:1183-1187
191. Himmelfarb J, McMonagle E, Holbrook D and Toth C (1995) Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis J Lab Clin Med 126:392-400
192. Hiramatsu M and Tsokos GC (1988) Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway. Clin Immunol Immunopathol 46:91-99
193. Hitomi Y and Fujii S (1982) Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol 69:262-267.
194. Hogg JC and Doerschui CM (1995) Leukocyte traffic in the lung. Annu Rev Physiol 57:97-114
195. Holguin MH, Fredrick LR, Bernshaw NJ, Wikox LA and Parker CJ (1989) Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84:7-17
196. Holliger P, Wing M, Pound JD, Bohlen H and Winter G (1997) Retargeting serum immunoglobulin with bispecific diabodies Nat Bitechnol 15:32-636.
197. Homemter JW and Lucchesi BR (1994) Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 34:17-40.
198. Homeister JW, Satoh PS, Kilgore KS and Lucchesi BR (1993) Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. J Immunol 150:1055-1064.
199. Homeister JW, Satoh P and Lucchesi BR (1992) Effects of complement activation in the isolated heart: Role of the terminal complement components. Circ Res 71:303-319.
200. Hong K, Kinoshita T, Miyazaki W, Izawa T and Inoue K (1979) An anticomplemen- tary agent, K-76 monocarboxylic acid: Its site and mechanism of inhibition of the complement activation cascade. J Immunol 122:2418-2423.
201. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G and Abramson SB (1988) Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31:32-641
202. Horstick G, Heimann A, Götze O, Hafner G, Berg O, Böehmer P, Becker P, Darius H, Rupprecht H-J, Loos M, Bhakdi S, Meyer J and Kempski O (1997) Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 95:701-708.
203. Hourcade D, Holers VM and Atkinson JP (1989) The regulators of complement activation (RCA) gene cluster. Adv Immunol 45:381-416
204. Hourcade D, Miesner D. R., Atkinson JP and Holers VM (1988) Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med 168:1255-1270
205. Hruby VJ (1997) Prospects for peptidomimetic drug design. Drug Discovery Today 2:165-167
206. Hu VW, Esser AF, Podack ER and Wisnieski BJ (1981) The membrane attack mechanism of complement: Photolabeling reveals insertion of terminal proteins into target membrane. J Immunol 127:380-386.
207. Hugh TE (1989) Structure and function of C3a anaphylaioxin. Curr Top Microbiol Immunol 153:181-208.
208. Hugli TE and Müller-Eberhard HJ (1978) Anaphylatoxins: C3a and C5a Adv Immunol 26:1-53.
209. Ikan N, Sakai Y, Hitomi Y and Kujii S (1983) New synthetic inhibitor to the alternative complement pathway. Immunology 49:685-691.
210. Inose K, Ono K, Tsutida A, Onai M, Komai M, Uchara K, Yano S and Naruse T (1997) Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis. Nephron 75:420-425.
211. Inverardi L, Samaja M, Motterlini R, Mangili F, Bender JR and Pardi R (1992) Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J Immunol 149:1416-1423.
212. Issekutz AC, Roland DM and Patrick RA (1990) The effect of FUT-175 (Nafamstat Mesilate) on C3a, C4a and C5a generation m vitro and inflammatory reactions in viuo. Int J Immunopharmacol 12:1-9.
213. Ivanovska N, Iossifova T and Kostova I (1996) Complement-mediated antiinflammatory action of extracts and pure secoiridoids isolated from Fraxinus species. Phytotherapy Res 10:555-558.
214. Ivanovska N and Philipov S (1996) Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloids. Int J Immunopharmacol 18:553-561.
215. Iwata K, Seya T, Ariga H and Nagasawa S (1994) Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary: Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein. J Immunol 152:3436-3444.
216. Jacob GS, Kirmaier C, Abbas SZ, Howard SC, Steininger CN, Welply JK and Scudder P (1995) Binding of sialyl Lewis X to E-selectin as measured by fluorescence polarization. Biochemistry 34:1210-1217.
217. Jakobovits A (1995) Production of fully human antibodies by transgenic mice. Curr Opin Biotechnol 8: 561-566.
218. Jaques LB (1979a) Heparin: An old drug with a new paradigm. Science 206:528-533
219. Jaques LB (1979b) Heparins: Anionic polyelectrolyte drugs. Pharmacol Rev 31:99-166.
220. Jenne D and Stanley KK (1985) Molecular cloning of S-protein: A link between complement, coagulation and cell-substrate adhesion. EMBO J 4:3153-3157.
221. Jenne DE and Tschopp J (1989) Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: Identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 86:7123-7127
222. Jensen JA (1969) A specific inactivator of mammalian C'4 isolated from nurse shark (Ginglymostoma cirratum) serum. J Exp Med 130:217-241.
223. Jiang H, Burdick D, Glabe CG, Cotman CW and Tenner AJ (1994) β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain J Immunol 152:5050-5059.
224. Johnson E, Berge V and Hogsen K (1994) Formation of the terminal complement complex on agarose beads: Further evidence that vitronectin (complement S-protein) inhibits C9 polymerization. Scand J Immunol 39:281-285.
225. Johnson SA, Lampert-Etchells M, Pasinetti CM, Rozovsky I and Finch CE (1992) Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging 13:641-648
226. Jungi TW and MeGregor DD (1979) Role of complement in the expression of delayedtype hypersensitivity in rats: Studies with cobra venom factor. Infect Immun 23:633-643.
227. Kaczorowski SL, Schiding JK, Toth CA and Kochanek PM (1995) Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J Cereb Blood Flow Hetab 15:860-864.
228. 2 chimeric complement inhibitor. J Exp Med 174:1451-1460.
229. Kalli KR, Hsu P and Fearon DT (1994) Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 15:417-431
230. Kaneko I, Fearon DT and Austen KF (1980) Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin. J Immunol 124:1194-1198.
231. Kaneko I, Kamoshida K and Takahashi S (1989) Complertatin, a potent anticomplement substance produced by Streptomyces lavendulae: Fermentation, isolation and biological characterization. J Antibiot 42:236-241
232. Kansas GS (1996) Selectins and their Uganda: Current concepts and controversies. Blood 88:3259-3287
233. Kasturi L. Chen HG and Shakin-Eshleman SH (1997) Regulation of N-linked core glycosylation: Use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr aequons that are poor oligosaccharide acceptors Biochem J 323:415-419.
234. Kaufman TS, Srivastava RP, Sindelar RO, Scesney SM and Marsh HC Jr (1995a) The design, synthesis and evaluation of A,C,D-ring analogs of the fungal metabolite K-76 as complement inhibitors: A potential probe for the absolute stereochemistry at position 2. Bioorg Med Chem Lett 5:501-506.
235. Kaufman TS, Srivastava RP, Sindelar RD, Scesney SM and Marsh HC Jr (1995b) Design, synthesis and evaluation of A/C/D-nng analogs of the fungal metabolite K-76 as potential complement inhibitors. J Med Chem 38:1437-1445.
236. Kawai M, Quincy DA, Lane B, Mollison KW, Luly JR and Carter GW (1991) Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J Med Chem 34:2068-2071.
237. Kawai M, Quincy DA, Lane B, Mollison KW, Or Y-S, Luly JR and Carter GW (1992) Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a J Med Chem 35:220-223.
238. Keams-Jonker MK, Cramer DV, Dane LA, Swensson JM and Makowka L (1997) Human serum reactivity to porcine endothelial cells after antisense-mediated down-regulation of GpIIIa expression. Transplantation 63:588-593.
239. Kemp PA, Spragg JH, Brown JC, Morgan BP, Gunn CA and Taylor PW (1992) Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and oeteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol 37:147-162.
240. Kennedy I and Sewell H (1998) Xenotransplantation moratorium. Nat Biotechnol 16:120.
241. Kennedy SP, Rollins SA, Burton WV, Sima PJ, Bothwell AL, Squinto SP and Zavoico GB (1994) Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 57:1494-1501.
242. Khazaeli MB, Conry RM and LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother 15:42-52.
243. Kilgore KS, Friedrichs GS, Homeister JW and Lucchesi BR (1994) The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 28:437-444
244. Kim S, Narayana SVL and Volanakis JE (1995) Crystal structure of o complement factor D mutant expressing enhanced catalytic activity. J Biol Chem 270:24399-24405
245. Kinoshita T, Medof ME, Hong K and Nussenzweig V (1986) Membrane-bound C4b interacts endogenouflly with complement receptor CR1 of human red cells. J Exp Med 164:1377-1388.
246. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE and Pacifico AD (1983) Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-857.
247. Kirschfink M, Blase L, Engelmann S and Schwartz-Albiez R (1997) Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J Immunol 158:1324-1331.
248. Kirezbaum L, Sharpe JA, Murphy B, d'Apice AJ, Classon B, Hudson P and Walker ID (1989) Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: A link between the complement and reproductive systems. EMBO J 8:711-718.
249. Kitano A, Matsumoto T, Nakamura S, Obata A, Oshitani N, Okawa K and Kobayashi K (1992) New treatment of ulcerative colitis with K-76. Dis Colon Rectum 35:560-567.
250. Kiyohara H, Cyong J-C and Yamada H (1989a) Relationship between structure and activity of an anticomplementary arabinogalactan from the roots of Angelica acutilona Kitagawa. Carbohydr Res 193:193-200.
251. Kiyohara H, Cyong J-C and Yamada H (1989b) Relationship between structure and activity of the "ramified" region in anti-complementary pectic polysaccharides from Angelica acutiloba Kitagawa Carbohydr Res 193:201-214.
252. Klickstein LB, Barbashov SF, Liu T, Jack RM and Nicholson-Weller A (1997) Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 7:345-355.
253. Klickstein LB, Bartow TJ, Miletic V, Kabson LD, Smith JA and Fcoron DT (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CRI, CD35) by deletion mutagenesis. J Exp Med 168:1699-1717
254. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG and Fearon DT (1987) Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3/C4 binding proteins. J Exp Med 165:1095-1112.
255. Kobayashi T, Neethling FA, Taniguchi S, Ye Y, Niekrasz M, Koren E, Hancock WW, Takagi H and Cooper DKC (1996) Investigation of the anti-complement agents, FUT-175 and K76COOH, in discordant xenotransplantation. Xenotransplantation 3:237-245.
256. Kotke C, Katayama A, Kadomatsu K, Hiraiwa N, Hayashi S, Kobayashi T, Hayash S, Yokoyama I and Takagi H (1997) Reduction of α-Gal epitopes in transgenic pig by introduction of human α1-2 fucosyltransferase. Transplant Proc 29:894.
257. Koike C, Kannagi R, Takuma Y, Akutsu F, Hayashi S, Hiraiwa N, Kadomatsu K, Muramatsu T, Yamakawa H, Nagui T, Kobayashi S, Okada H, Nakashima I, Uchida K, Yokoyama I and Takagi H (1996) Introduction of α(1,2)-fucosyltransferase and its effect on α-Ga1 epitopes in transgenic pig. Xenotransplantation 3:81-86.
258. Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P, Rosen H, Mumford RA and Springer MS (1994 ) Development of C5a receptor antagonists: Differential loss of functional responses. J Immunol 153:4200-4205.
259. Kontermann RE. Wing MG and Winter G (1997) Complement recruitment using bispecific diabodies. Nat Biotechnol 15:629-631
260. Kooyman DL, McClellan SB, Parker W, Avissar PL, Velardo MA, Platt JL and Logan JS (1996) Identification and characterization of a galartosyl peptide mimetic: Implications for use in removing xenoreactive anti-αGal antibodies. Transplantation 61:851-855.
261. Koren E, Milotic F, Neethling FA and Cooper DKC (1997) Neutralization of the cytotoxic effect of anti-αgal antibodies with monoclonal anti-idiotypic antibodies. in Xenotransplantation: The Transplantation of Organs and Tissues Between Species (Cooper DKC, Kemp E, Platt JL and White DJG. eds) 2nd ed, pp 377-386, Springer, Berlin.
262. Kosasi S, Hart LA, van Dijk H and Labadie RP (1989) Inhibitory activity of Jatropha multifida latex on classical complement pathway activity in human Berum mediated by a calcium-binding proanthocyanidin. J Ethnopharmacol 27:81-89.
263. Koski CL (1990) Characterization of complement-dung antibodies to peripheral nerve myelin in Guillain-Barre syndrome Ann Neural 27(Suppl.):S44-S47.
264. Koski CL, Sanders ME, Swoveland FT, Lawley TJ, Shin ML, Frank MM and Joiner KA (1987) Activation of terminal components of complement in patients with Guillain-Barre ayndrome and other demyelinating neuropathies. J Clin Invest 80:1492-1497.
265. Kossorotow A, Opitz W, Etachenberg E and Hadding U (1977) Studies on C3 convertases Inhibition of C5 convertase formation by peptides containing aromatic amino acids Biochem J 167:377-382.
266. Kourounakis L, Nelson RA Jr. and Kapusta MA (1973) The effect of a cobra venom factor on complement and adjuvant-induced disease in rats. Arthritis Rheum 16:71-76.
267. Kreil E, Montalescot G, Greene E, Fitzgibbon C, Robinson D, Chenoweth D and Zapol WM (1989) Nafamstat mesilate attenuates pulmonary hypertension in heparinprotamine reactions. J Appl Physiol 67:1463-1471.
268. Kretzschmar T, Pohl M, Casaretto M, Przewoeny M, Bautsch W, Klos A, Saunders D and Kohl J (1992) Synthetic peptides as antagonists of the anaphylatoxin C3a. Eur J Biochem 210:185-191.
269. Kroes BH, Beukelman CJ, van den Berg AJJ, Wolbink GJ, van Dijk H and Labadie RP (1997) Inhibition of human complement by β-glycyrrhetinic acid. Immunology 90:115-120.
270. Kroshus TJ, Bolman RM III and Dalmasso AP (1996a) Selective IgM depletion prolongs organ survival in an ex vivo model of pig-to-human Xenotransplantation. Transplantation 62:5-12
271. Kroshus TJ, Bolman RM III, Dalmasso AP, Rollins SA, Guilmette ER, Williams BL, Squinto SP and Fodor WL (1996b) Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 61:1513-1521.
272. Kroshus TJ, Rolling SA, Dalmasso AP, Elliot EA, Matis LA, Squinto SP and Bolman RM (1995) Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human Xenotransplantation. Transplantation 60:1194-1202.
273. Krumdieck R, Höök M, Rosenberg LC and Volanakis JE (1992) The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol 149: 3695-3701.
274. Krych M, Clemenza L, Howdeshell D, Hauhart R, Hourcade D and Atkinson JP (1994) Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 269:13273-13278.
275. Krych M, Hourcade D and Atkinson JP (1991) Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci USA 88:4353-4357.
276. Kubes P, Jutila M and Payne D (1995) Therapeutic potential of inhibiting leukocyte rolling in ischemia/reperfusion. J Clin Invest 95:2510-2519.
277. Kuttner-Kondo L, Medof ME, Brodbeck W and Shoham M (1996) Molecular modeling and mechanism of action of human decay-accelerating factor. Protein Eng 9:1143-1149.
278. Langlois PF, Gawryl MS, Zeller J and Lint T (1989) Accentuated complement activation in patient plasma during the adult respiratory distress syndrome: A potential mechanism for pulmonary inflammation. Heart & Lung 18:71-84.
279. Lasky LA (1992) Selectins: Interpreters of cell-specific carbohydrate information during inflammation. Science 258:964-969.
280. Lasky LA (1995) Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu Rev Biochem 64:113-139.
281. Latremouille C, Haeffner-Cavaillon N, Goussef N, Mandet C, Hinglais N, Bruneval P, Bariety J, Carpentier A and Glotz D (1994) Normal human polyclonal immunoglobulins for intravenous use significantly delay hyperacute xenograft rejection Transplant Proc 26:1285
282. Lawson JH and Platt JL (1996) Molecular barriers to xenotransplantation. Transplantation 62:303-310
283. Lefer AM (1995) Role of selecting in myocardial ischemia-reperfusion injury. Ann Thorac Surg 60:773-777.
284. Lefer AM, Weyrich AS and Buerke M (1994a) Role of selertins, a new family of adhesion molecules, in ischaemia-reperfusion injury. Cardiovasc Res 28:289-294
285. Lefer DJ, Flynn DM and Buda AJ (1996) Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion. Am J Physiol 270: H88-H98
286. X analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion. Circulation 90:2390-2401.
287. Lennon PF, Collard CD, Morrissey MA and Stahl GL (1996) Complement-induced endothelial dysfunction in rabbits: Mechanisms, recovery and gender differences Am J Physiol 270:H1924-H1932.
288. Lennon VA, Seybold ME, Lindstrom JM, Cochrane C and Ulevitch R (1978) Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 147:973-983
289. Lesavre P, Gaillard M-H and Halbwachs-Mecarelli L (1982) Inhibition of alternative pathway factor D by factor B-related synthetic hexapeptides. Eur J Immunol 12:252-254
290. Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ, Bolman RM III and Matas AJ (1993) Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55:857-866.
291. Leventhal JR, Sakiyalak P, Witson J, Simone P, Matas AJ, Bolman RM and Dalmasso AP (1994) The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 57:974-978.
292. Levin JL, Marsh HC Jr and Rudolph AR (1996) sCR1, a novel complement inhibitor: Development and potential applications for treating hyperacute rejection of transplanted organs, in Principles of Drug Development in Transplantation and Autoimmunity (Lieberman R and Mukherjee A. eds) pp 695-702, R.G. Landes Company, Austin, Texas.
293. Lima MCR, Prouvost-Danon A, e Silva PMR, Chagas MS, Calheiros AS, Cordeiro RSB, Latine D, Bazin H, Ryan USf Fit Martins MA (1997) Studies on the mechanisms involved in antigen-evoked pleural inflammation in rats. Contribution of IgE and complement. J Leukocyte Biol 61:286-292.
294. Lin C-C, Shimazaki M, Heck M-P, Aoki S, Wang R, Kimura T, Ritzen H, Takayama S, Wu S-H, Weitz-Schmidt Gf and Fit Wong C-H (1996) Synthesis of sialyl Lewis x mimetics and related structures using the glycosyl phosphite methodology and evaluation of E-selectin inhibition. J Am Chem Soc 118:6826-6840
295. Lin Y, Vandeputte M and Waer M (1997) Factors involved in rejection of concordant xenografts in complement-deficient rats. Transplantation 63:1705-1712.
296. Lindaay TF, Hill J, Ortiz F, Rudolph A, Valeri CR, Hechtman HB and Moore FD Jr.(1992) Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion. Ann Surgery 216:77-683.
297. Ling M, Piddlesden SJ and Morgan BP (1995) A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement din Exp Immunol 102:582-588.
298. Linhardt RJ, Rice KG, Kim YS, Engelken JD and Weiler JM (1988) Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity in hibit the generationof the amplification pathway C3 convertase in vitro. J Biol Chem 263:13090-13096
299. Liszewski MK and Atkinson JP (1996) Membrane cofactor protein (MCP: CD46): Isoforms differ in protection against the classical pathway of complement. J Immunol 156:4415-4421
300. Liszewski MK, Farries TC, Lublin DM. Rooney LA and Atkinson JP (1996) Control of the complement system. Adv Immunol 61:201-283.
301. Liszewski MK, Post TW and Atkinson JP (1991) Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 9:431-455.
302. Liu J, Qian Y and Holgersson J (1997) Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Galαal,3Gal epitope. Transplantation 63:1673-1682.
303. Ljunghusen O, Lundahl J, Nettelblad H, Nilsson B, Sjogren F and Stendahl O (1996) Endotoxemia and complement activation after severe burn injuries: Effects on leukocytes, soluble selectins and inflammatory cytokines. Inflammation 20:229-241.
304. Locher CP, Burch MT, Mower HF, Berestecky J, Davis H, Van Poel B, Lasure A, Vanden Berghe DA and Vlietinck AJ (1995) Anti-microbial activity and anticomplement activity of extracts obtained from selected Hawaiian medicinal plants J Ethnopharmacol 49:23-32.
305. López-Trascasa M, Bing DH, Rivard M and Nicholson-Weller A (1989) Factor J: Isolation and characterization of a new polypeptide inhibitor of complement C1 J Biol Chem 264:16214-16221.
306. Lowe JB and Ward PA (1997) Therapeutic inhibition of carbohydrate-protein interactions in vivo. J Clin Invest 99:822-826
307. Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, Recht PA, Golden B and Cronstein BN (1995) Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA 92:8378-8382
308. 2-glycoprotein I. Proc Natl Acad Sci USA 81:3640-3644.
309. Lukas TJ, Munoz H and Erickson BW (1981) Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G. J Immunol 127:2555-2560
310. Maaheimo H, Renkonen R, Turunen JP, Penttila L and Renkonen O (1995) Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion: Evidence that multivalency enhances the sacchande binding to L-selectin. Eur J Biochem 234:616-625
311. Mackay CR and Imhof BA (1993) Cell adhesion in the immune system. Immunol Today 14:99-102.
312. Magee JC, Collins BH, Harland RC, Lindman BJ, Bollinger RR, Frank MM and Platt JL (1995) Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation J Clin Invest 96:2404-2412.
313. Maillet F, Kazatchkine MD, Glotz D, Fischer E and Rowe M (1983) Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 20:1401-1404.
314. Makrides SC, Nygren P-Å, Andrews B, Ford PJ, Evans KS, Hayman EG, Adari H, Levin J, Uhlén M and Toth CA (1996) Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharnacol Exp Ther 277:534-542.
315. Makrides SC and Ryan US (1997) Complement inhibition in ischemia reperfusion injury, in Ischaemia Reperfusion Syndrome (Grace PA and Mathie RT, eds) in press, Blackwell Science, Oxford.
316. Makrides SC, Scesney SM, Ford PJ, Evans KS, Carson GR and Marsh HC Jr.(1992) Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster wary cells from lysis by human complement. J Biol Chem 267:24754-24761
317. Malhotra R, Willis AC, Jensemus JC, Jackson J and Sim KB (1993) Structure and homotogy of human C1q receptor (collertin receptor). Immunology 78:341-348.
318. Malik AB and Lo SK (1996) Vascular endothelial adhesion molecules and tissue inflammation. Pharmacol Rev 48:213-229.
319. Manning DD, Hu X, Beck P and Kiessling LL (1997) Synthesis of sulfated neogly-copolymers Selective P-selectin inhibitors. J Am Chem Soc 119:161-3162.
320. Marah HC and Ryan US (1997) Therapeutic effect of soluble complement receptor type 1 in xenotransplatation, in Xenotransplantation: The Transplantation of Organs and Tissues Between Species (Cooper DKC. Kemp E, Platt JL and White DJG, eds) 2nd ed, pp 437-455, Springer, Berlin
321. Martens CL, Cwirla SE, Lee RYW, Whitehorn E, Chen EYF, Bakker A, Martin EL, Wagstrom C, Gopalan P, Smith CW, Tate E, Koller KJ, Schatz PJ, Dower WJ and Barrett RW (1995) Peptides which bind to E-selectin and block neutrophil adhesion. J Biol Chem 270:21129-21136.
322. Matis LA and Rollins SA (1995) Complement-specific antibodies: Designing novel anti-inflammatories Nat Med 1:839-842.
323. McCormick LL, Karulin AY, Schreiber JR and Greenspan NS (1997) Bispecific antibodies overcome the opsonin-reotjptor mismatch of cystic fibrosis in vitro: Restoration of neutrophil-mediated phagocytosis and killing of Pseudomonas aeruginosa J Immunol 158:3474-3482.
324. McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS and Platt JL (1995a) Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury Nat Med 1:423-427
325. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS and Platt JL (1995b) Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 59:1177-1182.
326. McDonald JF and Nelsestuen GL (1997) Potent inhibition of terminal complement assembly by clusterin: Characterization of its impact on C9 polymerization. Biochemistry 36:7464-7473.
327. McEver RP, Moore KL and Cummings RD (1995) Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 270:11025-11028
328. McGeer PL, Walker DC, Pitas RE, Mahley RW and McGeer EG (1997) Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates β-amyloid protein activation of complement in vitro. Brain Res 749:135-138.
329. Meade P, Shoemaker WC, Donnelly TJ, Abraham E, Jagels MA, Cryer HG, Hugli TE, Bishop MH and Wo CC (1994) Temporal patterns of hemodynamics, oxygen transport, cytokine activity and complement activity in the development of adult respiratory distress syndrome after severe injury. J Trauma 36:651-657.
330. Medof ME, Iida K, Mold C and Nussenzweig V (1982) Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 156:1739-1754.
331. Medof ME, Kinoshita T and Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558-1578.
332. Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Lcykam JF, Atkinson JP and Tykocinski ML (1987) Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci USA 84:2007-2011.
333. Medof ME, Nagarajan S and Tykocinski ML (1996) Cell-surface engineering with GPI-anchored proteins. FASEB J 10:574-586.
334. Medof ME, Walter EI, Roberts WL, Haas R and Rosenberry TL (1986) Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 28:6740-6747.
335. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H and Lachmann PJ (1990) Human protectin (CD59): An 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1-9.
336. Miller CG, Cook DN and Kotwal GJ (1996) Two chemotactic factors, C5a and MIP-1α, dramatically alter the mortality from Zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to mods while MIP-1α has a protective role. Mol Immunol 33:1135-1137.
337. Mitomo K, Fujita T and Iida K (1987) Functional and antigenic properties of complement receptor type 2, CR2. J Exp Med 165:1424-1429.
338. Miyagawa S, Hirose H, Shirakura R, Naka Y, Nakata S, Kawashima Y, Seya T, Matsumoto M, Uenaka A and Kitamura H (1988) The mechanism of discordant xenograft rejection. Transplantation 46:825-830.
339. Miyagawa S, Shirakura R, Izutani H, Matsumiya G, Nakata S, Matsuda H, Iwata K, Nagasawa S, Terado A, Matsumoto M and Seya T. (1994) Effect of transfectant molecules, MCP, DAF and MCP/DAF hybrid on xenogeneic vascular endothelium. Transplant Proc 26:1253-1254.
340. Miyagawa S, Shirakura R, Matsumiya G, Fukushima N, Nakata S, Matsuda H, Matsumoto M, Kitamura H and Seya T (1993) Prolonging discordant xenograft. survival with anticomplement reagents K76COOH and FUT175 Transplantation 55:709-713.
341. Miyagawa S, Shirakura R, Nakata S, Izutani H, Matsuda H, Iwata K, Nagasawa S, Terado A, Hatanaka M, Matsumoto M and Seya T (1995) Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55). Transplant Proc 27:328-329.
342. Miyazaki W, Izawa T, Nakano Y, Shinohara M, Hing K, Kinoshita T and Inoue K (1984) Effects of K-76 monocarboxylic acid, an anticomplementary agent, on various in vivo immunological reactions and on experimental glomerulonephritis. Complement 1:134-146.
343. Miyazaki W, Tamaoka H, Shinohara M, Kaise H, Izawa T, Nakano Y, Kinoshita T, Hong K and Inoue K (1980) A complement inhibitor produced by Stachybotrys complement!, nov. sp. K-76: A new species of fungi imperferti. Microbiol Immunol 24:1091-1108.
344. Mollison KW, Krause RA, Fey TA, Miller L, Wiedeman PE, Kawai M, Lane B, Luly JR and Carter GW (1992) Hexapeptide analogs of C5a anaphylatoxin reveal heterogeneous neutrophil agonism/antagonism. FASEB J 6-A2058
345. Mollnes TE (1997) Biocompatibility: Complement as mediator of tissue damage and as indicator of incompatibility. Exp Clin Immunogenet 14:24-29
346. Momota K, Kaneko I, Kimura S, Mitamura K and Shimada K (1991) Inhibition of human immunodeficiency virus type-1-induced svncytium formation and cytopathicity by complestatin Biohem Biophys Ret Commun 17:243-250
347. Moore MD, Cooper NR, Tack BF and Nemerow GR (1987) Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci USA 84:194-9198.
348. Moran P, Beasley H, Gorrell A, Martin E, Gribling P, Fuchs H, Gillett N, Burton LE and Caras IW (1992) Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 149:1736-1743.
349. Morgan BP (1990) Complement: Clinical Aspects and Relevance to Disease Academic Press, Inc., Boston.
350. Morgan BP (1992) Effects of the membrane attack complex of complement on nucleated cells Curr Top Microbiol Immunol 178:115-140
351. Morgan BP (1994) Clinical complementology: Recent progress and future trends. Eur J Clin Invest 24: 219-228.
352. Morgan BP (1995a) Complement regulatory molecules Application to therapy and transplantation. Immunol Today 16:257-259.
353. Morgan BP (1995b) Physiology and pathophysiology of complement Progresa and trends. Crit Rev Clin Lab Sci 32:265-298
354. Morgan BP, Casque P, Singhrao SK and Piddlesden SJ (1997) Role of complement in inflammation and injury in the nervous system. Exp Clin Immunagenet 14:19-23
355. Morgan BP and Meri S (1994) Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 16:369-396.
356. Morgan EL (1986) Modulation of the immune response by anaphylatoxins. Complement 3:128-136
357. Morris PJ (1996) A critical review of immunosuppreasive regimens. Transplant Proc 28:37-40.
358. Mornson SL and Shin SU (1995) Genetically engineered antibodies and their application to brain delivery. Advanced Drug Delivery Rev 15:147-175.
359. Mosaakowska DE and Smith RAG (1997) Complement receptors and their therapeutic applications, in Recombinant Cell Surface Receptors: Focal Point for Therapeutic Intervention (Browne MJ, ed) pp 209-220, R. G. Landes Co., Georgetown, Texas.
360. Muller-Eberhard HJ (1988) Molecular organization and function of the complement system. Annu Rev Biochem 57:321-347
361. Müller-Eberhard HJ and Fjellstroom K-E (1971) Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol 107:1666-1672.
362. Mulligan MS, Miyasaka M, Suzuki M, Kawashima H, Iizuka M, Hasegawa A, Kiso M, Warner RL and Ward PA (1995) Anti-inflammatory effects of sulfatides in selectin-dependent acute lung injury [published erratum appears in Int. Immunol. 1995 Oct;7(10):1699] Int Immunol 7:1107-1113.
363. Mulligan MS, Paulson JC, DeFrees S, Zheng ZL, Lowe JB and Ward PA (1993a) Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature 364:149-151.
364. Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Brauer RB, Hugli TE, Miyasaka M, Warner RL, Johnson KJ and Ward PA (1996) Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 98:503-512.
365. Mulligan MS, Schmid E, Till GO, Hugli TE, Friedl HP, Roth RA and Ward PA (1997) C5a-dependent up-regulation in vivo of lung vascular P-selectin. J Immunol 158: 1857-1861.
366. Mulligan MS, Warren JS, Smith CW, Anderson DC, Yeh CG, Rudolph AR and Ward PA (1992a) Lung injury after deposition of IgA immune complexes: Requirements for CD18 and L-arginme. J Immunol 148:3086-3092.
367. Mulligan MS, Watson SR, Fennie C and Ward PA (1993b) Protective effects of selectin chimeras in neutrophil-mediated lung injury. J Immunol 151:6410-6417.
368. Mulligan MS, Yeh CG, Rudolph AR and Ward PA (1992b) Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J Immunol 148:1479-1485.
369. Murohara T, Buerke M and Lefer AM (1996) Cardioprotective actions of oligotide, a single stranded polydeoxyribonucleotide complex, in myocardial ischaemia and reperfusion injury. Br J Pharmacol 117:1000-1008.
370. Murohara T, Guo J, Delyani JA and Lefer AM (1995a) Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find Exp Clin Pharmacol 17:499-507.
371. Murohara T, Guo JP and Lefer AM (1995b) Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. J Pharmacol Exp Ther 274:1246-1253.
372. x-oligosaccharido in myocardial ischaemia and reperfusion injury. Cardiovasc Res 30:965-974
373. Murphy BF, Saunders JR. O'Bryan MK, Kirszbaum L, Walker ID and d'Apice AJ (1989) SP-40,40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol 1:551-554
374. Murphy FA (1996) The public health risk of animal organ and tissue transplantation into humans. Science 273:746-747.
375. Nainggolan L (1996) Xenotransplantation - saving our bacon?' Scrip December:38-42.
376. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Kabourdin-Combe C and Gerlier D (1993) Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67:6025-6032.
377. Narayana SV, Carson M, el-Kabbani O, Kilpatrick JM, Moore D, Chen X, Bugg CE, Volanakis JE and DeLucas LJ (1994) Structure of human factor D: A complement system protein at 2.0 Å resolution. J Mol Biol 235:695-708
378. Navia MA (1996) Protein-drug complexes important for immunoregulation and organ transplantation Curr Opin Struct Biol 6:838-847.
379. Negoro N, Okamura M, Takeda T, Koda S, Amatsu K, Inoue T, Curd JG and Kanayama Y (1989) The clinical significance of iC3b neoantigen expression in plasma from patienta with systemic lupus erythematosus. Arthritis Rheum 32: 1233-1242
380. Nelson RA (1953) The immune-adherence phenomenon: An immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 118:733-737.
381. Nelson RA (1955) The immune-adherence phenomenon: A hypothetical role of erythrocytes in defense against bacteria and viruses. Proc R Soc Med 49:55-58.
382. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ and Bevilacqua MP (1993) Heparin oligooaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253-3258.
383. Nepomuceno RR, Henschen-Edman AH, Burgess WH and Tenner AJ (1997) cDNA cloning and primary structure analysis of C1qRfP), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity 0:119-129.
384. Nicholson-Weller A, Burge J, Fearon DT, Weller PF and Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotem with decay-accelerating activity for C3 convertais of the complement system. J Immunol 129:184-189.
385. Nicholson-Weller A and Halperin JA (1993) Membrane signalling by complement C5b-9. the membrane attack complex. Immunol Res 12:244-257.
386. Nicholson-Weller A and Wang CE (1994) Structure and function of decay accelerating factor CD55. J Lab Clin Med 123:485-491.
387. N'iculescu F, Hugo F, Rus HG, Vlaicu R and Bhakdi S (1987) Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atheroaclerotk arteries. Clin Exp Immunol 88:477-483.
388. Norman KE, Scheding C, Kunkel EJ, Hearaer GA and Ley K (1996) Peptides derived from the lectin domain of selectin adhesion molecules inhibit leukocyte rolling in vivo. Microcirculation 3:29-38.
389. O'Connell D, Koenig A, Jennings S, Hicke B, Han HL, Fitzwater T, Chang YF, Varki N, Parma D and Varki A (1996) Calcium-dependent oligonucleotide antagonists specific for L-selectin. Proc Natl Acad Sci USA 93:5883-5887.
390. Ogata RT and Low PJ (1997) Complement-inhibiting peptides identified by proximity to indels in the C3/4/5 protein family J Immunol 158:3852-3860
391. Ogata RT, Mathias P, Bradt BM and Cooper NR (1993) Murine C4b-binding protein. Mapping of the ligand binding site and the N-terminus of the pre-protein. J Immunol 150:2273-2280
392. Oglesby TJ, Allen CJ, Liszewski MK, White DJ and Atkinson JP (1992) Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 175:1547-1551.
393. Okada N, Liszewski MK, Atkinson JP and Caparon M (1995) Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus Proc Natl Acad Sci USA 92:2489-2493.
394. Oldham KT, Guice KS, Till GO and Ward PA (1988) Evidence of local complement activation in cutaneous thermal injury in rats. Prag Clin Biol Res 264:421-424
395. Or YS, Clark RF, Lane B, Mollison KW, Carter GW and Luly JR (1992) Improvements in the minimum binding sequence of C5a: Examination of His-67. J Med Chem 35:402-406.
396. Oriol R and Cooper DKC (1997) Major carbohydrate Xenotransplantation antigens, in Xenotransplantation: The Transplantation of Organs and Tissues Between Species (Cooper DKC, Kemp E, Platt JL and White DJG, eds) 2nd ed. pp 24-32, Springer, Berlin
397. Pardi R, Inverardi L and Bender JR (1992) Regulatory mechanisms in leukocyte adhesion: Flexible receptors for sophisticated travelers Immunol Today 13:224-230,
398. Parker CJ (1992) Regulation of complement by membrane proteins: An overview. Curr Top Microbiol Immunol 178:1-7.
399. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M and Platt JL (1996) Transplantation of discordant xenografts: A challenge revisited. Immunol Today 17: 373-378.
400. Pascher A, Poehlein C, Stangl M, Hoebel G, Thiery J, MuellerDerlich J and Hammer C (1997) Application of immunoapheresis for delaying hyoeracute rejection during isolated xenogeneic pig liver perfusion. Transplantation 63:867-875.
401. Pascual M and French LE (1995) Complement in human diseases: Looking towards the 21st century Immunol Today 16:58-61
402. Pasinetti GM (1996) Inflammatory mechanisms in neurodegeneration and AJzheimer's disease: The role of the complement system. Neurobiol Aging 17:707-716.
403. Patience C, Takeuchi Y and Weiss RA (1997) Infection of human cells by an endogenous retrovirus of pigs. Nat Med 3:282-286.
404. Patrick RA and Johnson RE (1980) Complement inhibitors, in Annual Reports in Medicinal Chemistry (Hess H-J. ed) vol 15, pp 193-201, Academic Press, New York
405. Peerschke EI, Malhotra R. Ghebrehiwet B, Reid KB, Willis AC and Sim RB (1993) Isolation of a human endothelial cell C1q receptor (C1qR). J Leukocyte Biol 53:179-184
406. Peerschke EI, Smyth SS, Teng EI, Dalzell M and Ghebrehiwet B (1996) Human umbilical vein endothelial cells possess binding sites for the globular domain of C1q J Immunol 157:4154-4158.
407. Pemberton M, Anderson G, Vetvicka V, Justus DE and Ross CD (1993) Microvascular effects of complement blockade with soluble recombinant CRI on ischemia/ reperfusion injury of skeletal muscle. J Immunol 150:5104-5113.
408. x. Science 250:1130-1132.
409. Picard MD, Pettey CL, Marsh HC Jr. and Thomas LJ (1996) Sequence analysis of N-linked oligosacchandes bearing sialyl Lewis x moieties on soluble complement receptor type 1 (sCRD. Glycobiology 6:766.
410. Piddlesdcn SJ. Jiang SS, Levin JL, Vincent A and Morgan BP (1996) Soluble complement receptor 1 (sCRD protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 71:173-177.
411. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H and Morgan BP (1994) Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelmating experimental allergic encephalomyelitis. J Immunol 152:5477-5484.
412. Platt JL (1996) The immunological barriers to Xenotransplantation. Crit Rev Immunol 16:331-358.
413. Platt JL, Lindman BJ, Geller RL, Noreen HJ, Swanson JL, Dalmasso AP and Bach FH (1991) The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 52:1037-1043.
414. Platt JL and Logan JS (1997) Use of transgenic animals as xenotransplant donors, in Xenotransplantation: The Transplantation of Organs and Tissues Between Spe- cies (Cooper DKC, Kemp E, Platt JL and White DJG. eds) 2nd ed. pp 650-658. Springer, Berlin.
415. Podack ER, Kolb WP and Müller-Eberhard HJ (1977) The SC5b-7 complex: Formation, isolation, properties and subunit composition. J Immunol 119:2024-2029.
416. Ftodack ER and Müller-Eberhard HJ (1979) Isolation of human S-protein, an inhibitor of the membrane attack complex of complement J Biol Chem 254:9908-9914
417. Podack ER. Müller-Eberhard HJ, Horst H and Hoppe W (1982) Membrane attack complex of complement (MAC): Three-dimensional analysis of MAC-phospholipid vesicle recombinants. J Immunol 128:2353-2357
418. Polley MJ, Phillips ML. Wayner E, Nudelman E, Singhal AK, Hakomori S and Paulson JC (1991) CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x. Proc Natl Acad Sci USA 88:224-6228.
419. Popeacu C, Croitoru M and Gancevici GG (1988) Natural inhibitors of complement: Systemic toxicity of the complement inhibitor from pokeweed fruits and the effect of antiozidizing enzymes, glutathione and phenobarbital. Arch Roum Pathol Exp Microbiol 47:37-41.
420. Pratt JR, Hibbs MJ, Laver AJ, Smith RAG and Sacks SH (1996a) Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 149:2055-2066.
421. Pratt JR, Hibbs MJ, Laver AJ, Smith RA and Sacks SH (1996b) Allograft immune response with sCR1 intervention. Transpl Immunol 4:72-75.
422. Preissner KT (1991) Structure and biological role of vitronectin. Annu Rev Cell Biol 7:275-310.
423. Pruitt SK, Baldwin WM III, Barth RN and Sanfilippo F (1993) The effect of xenoreactive antibody and B cell depletion on hyperacute rejection of guinea pig-to-rat cardiac xenografts. Transplantation 56:1318-1324.
424. Pruitt SK, Bollinger RR, Collins BH, Marsh HC Jr , Levin JL. Rudolph AR, Baldwin WM III and Sanfilippo F (1997) Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-pnmate cardiac xenografts. Transplantation 63:900-902.
425. Quigg RJ (1992) Inhibition of the alternative pathway of complement by glomerular cfaondroitin sulphate proteoglycan. Immunology 76:373-377.
426. Rabinovici R, Yeh CG, Hillegass LM, Griswold DE, DiMartino MJ, Vernick J, Fong K-L and Feuerstein G (1992) Role of complement in endotoxin/platelet-activating factor-induced lung injury J Immunol 149:1744-1750
427. Rao BNN, Anderson MB, Musner JH, Gilbert JH, Schaefer ME, Foxall C and Brandley BK (1994) Sialyl Lewis X mimics derived from a pharmacophore search are selectin inhibitors with anti-inflammatory activity. J Biol Chem 269:19663-19666
428. Rapley R (1995) The biotechnology and applications of antibody engineering. Mol Biotechnol 3:139-154.
429. RegaJ JF and Fraser DG (1996) Systemic complement system depletion does not inhibit cellular accumulation in antihistamine pretreated allergic guinea pig lung. Int Arch Allergy Immunol 109:150-160.
430. Regal JF, Fraser DG and Toth CA (1993) Role of the complement system in antigen induced bronchoconstriction and changes in blood pressure in the guinea pig. J Pharmacol Exp Ther 267:979-988.
431. Reid KB (1986) Activation and control of the complement system. Essays Biochem 22:27-68.
432. Reid KBM and Day AJ (1989) Structure-function relationships of the complement components. Immunol Today 10:177-180.
433. Reid KBM, Sim RB and Faiers AP (1977) Inhibition of the reconstitution of the hemolytic activity of the first component of human complement by a pepsinderived fragment of subcomponent C1q Biochem J 161:239-245
434. a pentasacchande J Appl Physiol 82:1058-1063
435. Reilly BD, Makrides SC, Ford PJ, Marsh HC Jr and Mold C (1994) Quantitative Analysis of C4b Dimer Binding to Distinct Sites on the C3b/C4b Receptor (CRL). J Biol Chem 289:7696-7701
436. Reinagel ML, Gezen M, Ferguson PJ, Kuhn S, Martin EN and Taylor RP (1997) The primate erythrocyte complement receptor (CR1) as a privileged site Binding of unmunoglobulin G to erythrocyte CR1 does not target erythrocytes for phagocytosis. Blood 89:1068-1077
437. Reist CJ, Combs MJ, Croft BY and Taylor RP (1993) Antigens pre-bound to the Primate erythrocyte complement receptor via cross-linked bispecific monoclonal antibody heteropolymers are rapidly cleared from the circulation Eur J Immunol 2:3021-3027
438. Reist CJ, Liang HY, Denny D, Martin EN, Scheid WM and Taylor RP (1994) Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys. Eur J Immunol 24:2018-2025
439. Rey-Campos J, Rubinstein P and Rodriguez de Cordoba S (1987) Decay-accelerating Actor: Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans J Exp Med 166:246-252
440. Rinaldo JE and Christman JW (1990) Mechanisms and mediators of the adult respiratory distress syndrome Clin Chest Med 11:621-632
441. Rhoder CS, Rinder HM, Smith BR, Pitch JC, Smith MJ, Tracey JB, Malis LA, Sqninto SP and Rollins SA (1995) Blockade of C5a and C5b-9 generation inhibits lecukocyte and platelet activation during extracorporeal circulation. J Clin Invert 96:1564-1572
442. Ripoche J, Day AJ, Harris TJ and Sim RB (1988) The complete amino acid sequence of human complement factor H. Biochem J 249:593-602
443. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH. Braehova L, Bradt B, Ward P and Lieberburg I (1992) Complement activation by β-amyloid in Alzheimer disease Proc Natl Acad Sci USA 89:10016-10020
444. Roglie A, Prounitz ER, Cavanagh SL, Pan Z, Zou A and Ye RD (1996) cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure Biochem Btophys Acta 1205:39-43.
445. Rollins SA, Malis LA, Springhorn JP, Setter E and Wolff DW (1995) Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 60:1284-1292.
446. Rollins SA, Zhao J, Ninomiya H and Sims PJ (1991) Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunot 146:2345-2351
447. Romanella M, Aminian A, Adam WR, Pearse MJ and d'Apice AJF (1997) Involvement of both the classical and alternate pathways of complement in an ex vivo model of xenograft rejection. Transplantation 63:1021-1025.
448. Rosen SD and Bertozzi CR (1994) The selectins and their ligands Curr Opin Cell Biol 6:663-673
449. Rosenberg ME and Silkensen J (1995) Clusterin: Physiologic and pathophysiologlc considerations. Int J Biochem Cell Biol 27:633-645
450. Ross GD (1986) Immunobiology of the Complement System. Academic Press, Boston.
451. Ross SC and Densen P (1984) Complement deficiency states and infection: Kpidemiology. pathogenesis and consequences of neisserial and other infections in an immune deficiency Medicine 63:243-273.
452. Rosse WF (1997) Paroxysmal nocturnal hemoglobinuna as a molecular disease, Medicine 76:63-93.
453. Rother K and Till GO (1988) The Complement System. Springer-Verlag, New York
454. Rother RP, Fodor WL, Springhorn JP, Birks CW. Setter E. Sandnn MS, Squinto SP and Rollins SA (1995) A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J Exp Med 182:1345-1355
455. Rother RP and Squinto SP (1996) The α-galactosyl epitope: A sugar coating that makes viruses and cells unpalatable. Cell 86:185-188
456. Rubin B, Smith A, Romaschin A and Walker P (1989) Participation of the complement system in ischemia/reperfusion injury. Microcirc Endothelium Lymphatics 5:207-221.
457. Rushmere NK, Tomlinson S and Morgan BP (1997) Expression of rat CD59: Functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function. Immunology 90:640-646.
458. Ryan US (1995) Complement inhibitory therapeutics and xenotransplantation. Nat Med 1:967-968
459. Saadi S, Ihrcke NS and Platt JL (1996) Pathophysiology of xenograft rejection, in Principles of Drug Development in Transplantation and Autoimmunity (Lieberman R and Mukherjee A, eds) pp 31-45, R.G. Landes Company, Austin, Texas.
460. Sahu A, Kay BK and Lambns JD (1996) Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 157:884-891.
461. Sanders ME, Koski CL, Robbins IJ, Shin ML, Frank MM and Joiner KA (1986) Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol 136:4456-4459.
462. Sandrin MS, Cohney S, Osman N and McKenzie IFC (1997) Overcoming the antigalα(1-3)gal reaction to avoid hyperacute rejection: Molecular genetic approaches, in Xenotransplantation: The Transplantation of Organs and Tissues Between Species (Cooper DKC, Kemp E, Platt JL and White DJG, edst 2nd ed. pp 683-700, Springer, Berlin.
463. Sandrin MS, Fodor WL, Mouhtouris E, Osman N, Cohney S, Rollins SA, Guilmette ER, Setter E, Squinto SP and McKenzie IFC (1995) Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1:1261-1267.
464. Sanfilippo F (1996) Exogenous complement inhibition in xenotransplantation. Xeno 4:1-4.
465. Satsuma S, Scudamore RA, Cooke TD, Aston WP and Saura R (1993) Toxicity of complement for chondrocytes: A possible source of cartilage degradation in inflammatory arthritis. Rheumatol Int 13:71-75.
466. Scesney SM, Makrides SC, Gosselm ML, Ford PJ, Andrews BM, Hayman EG and Marsh HC Jr. (1996) A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway Eur J Immunol 26:1729-1735.
467. Schaapherdcr AF, Daha MR, te Bulte MT, van der Woude FJ and Gooszen HG (1994) Antibody-dependent cell-mediated cytotoxicity against porcine endothettum induced by a majority of human sera. Transplantation 57:1376-1382.
468. Schifferli JA. Ng YC and Peters DK (1986) The role of complement and its receptor in the elimination of immune complexes N Engl J Med 315:488-495
469. Schmid E, Piccolo M-TS, Friedl HP, Warner RL, Mulligan MS, Hugh TE, Till GO and Ward PA (1997a) Requirement for C5a in lung vascular injury following thermal trauma to rat skin Shock 8:119-124.
470. Schmid E, Warner RL, Crouch LD, Friedl HP, Till GO, Hugh TE and Ward PA (1997b) Neutrophil chemotactic activity and C5a following systemic activation of complement m rats. Inflammation 21:325-333.
471. Schwartz HJ and Naff GB (1971) The effect of complement depletion by cobra venom factor on delayed hypereensitivity reactions Proc Soc Exp Biol Med 138:1041-1043.
472. x. J Pathol 180:305-310.
473. Sen AC, Picard MD, Mealey R, Bertino A and Thomaa LJ (1966) Monosacchande composition indicates presence of Lewis antigen in oligoaaccharides in an alternatively glycosylated form of soluble complement receptor 1 Glycobiology 6:766
474. Seto H, Fujioka T, Furihata K, Kaneko I and Takahauni S (1989) Structure of compleatatin, a very strong inhibitor of protease activity of complement in the human complement system. Tetrahedron Lett 30:4987-4990
475. Seya T, Turner JR and Atkiiuon JP (1986) Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b J Bip Med 163:837-855
476. Shandelya SML, Kuppusamy P, Herskowitz A, Weisfeldt ML and Zweier JL (1993) Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart: Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation 88: 2812-2826.
477. Sharma AK and Pangburn MK (1996) Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagensis. Proc Natl Acod Sci USA 93:10996-11001.
478. Sharma A, Okabe J, Birch P, McClellan SB, Martin MJ, Platt JL and Logan JS (1996) Reduction in the level of Gal(α1,3)Gal in tranigenic mice and pigs by the expression of an (1,2)fucosyltransferase. Proc Natl Acad Sci USA 93:7190-7195.
479. Shaw DR, Rustagi PK, Kandimalla ER, Manning AN, Jiang ZW and Agrawal S (1997) Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol 63:1123-1132.
480. Sheehan M, Morris CA, Pussell BA and Charlesworth JA (1995) Complement inhibition by human vitronectin involves non-heparin binding domains. Clin Exp Immunol 101:136-141
481. Shennan-Gold R (1997) Monoclonal antibodies: The evolution from '80s magic bullets to mature, mainstream applications as clinical therapeutics. Gen Engineering Newt 17:4 and 35.
482. Shichishima T (1995) Glycosylphosphatidylinositol (GPI)-anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Fukushima J Med Sci 41:1-13
483. Sindelar RD, Bradbury BJ, Kaufinan TS, Ip SH. Marsh Jr HC and Lee C (1996) Compounds that inhibit complement and/or suppress immune activity. U.S. Patent Number 5,506,247.
484. Smith EF III, Griawold DE, Egan JW, Hillegass LM, Smith RAG, Hibbs MJ and Gagnon RC (1993) Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). Bur J Pharmacol 238:477-481.
485. Scares M, Lu X, Havaux X, Baranski A, Reding R, Latinne D. Daha M, Lambotte L, Bach FH and Bazin H (1994) In vivo IgM depletion by anti-μ monoclonal antibody therapy: The role of IgM in hyperacute vascular rejection of discordant xenografts Trantplantation 57:1003-1009.
486. Spitzer RE, Vallota EH, Forristal J, Sudora E, Stitzel A, Davis NC and West CD (1969) Serum C3 lytic system in patients with glomerulonephritis. Science 104: 436-437.
487. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration. The multistep paradigm. Cell 76:301-314
488. Squinto SP and Fodor WL (1997) Engineering of xenografts to provide organs for human transplantation, in Xenotransplantation: The Transplantation of Organs and Tissues Between Species (Cooper DKC, Kemp E, Platt JL and White DJG, eds) 2nd ed, pp 659-664, Springer, Berlin.
489. Stoye JP (1997) Proviruses pose potential problems Nature 386:126-127.
490. Stoye JP and Coffin JM (1995) The dangers of xenotransplantation. Nat Med 1:1100.
491. Stuart GR, Lynch NJ, Lu J, Geick A, Moffatt BE, Sim RB and Schwaeble WJ (1996) Localisation of the Clq binding site within Clq receptor/calreticulin. FEBS Lett 397:245-249.
492. Sugita Y, Ito K, Shiozuka K, Suzuki H, Gushima H, Tomita M and Masuho Y (1994) Recombinant soluble CD59 inhibits reactive haemolysis with complement. Immunology 82:34-41.
493. Sugita Y, Nakano Y, Oda E, Noda K, Tobe T, Miura NH and Tomita M (1993) Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59): A glycosyl-phosphatidylinositol-anchored membrane protein. J Biochem 114:473-477.
494. Sugita Y, Tobe T, Oda E, Tomita M, Yasukawa K, Yamaji N, Takemoto T, Furuichi K, Takayama M and Yano S (1989) Molecular cloning and characterization of MACIF: An inhibitor of membrane channel formation of complement. J Biochem 106:555-557.
495. Suzuki H, Yamaji N, Egashira A, Yasunaga K, Sugita Y and Masuho Y (1996) Effect of the sugar chain of soluble recombinant CD59 on complement inhibitory activity FEBS Lett 399:272-276.
496. Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD and Ruoslahti E (1985) Complete amino acid sequence of human vitronectin deduced from cDNA: Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 4:2519-2524.
497. Takahashi T, Saadi S and Platt JL (1997) Recent advances in the immunology of xenotransplantation. Immunologic Res 16:273-297.
498. Tanaka M, Murase N, Ye Q, Miyazaki W, Nomoto M, Miyazawa H, Manez R, Toyama Y, Demetris AJ, Todo S and Starzl TE (1996) Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. Transplantation 62:681-638.
499. Tanemura M, Miyagawa S, Ihara Y, Mikata S, Matsuda H, Shirakura R and Taniguchi N (1997a) Reduction of the major swine xenoantigen GALα(1,3)GAL by transfection of N-acetylglucosaminyl transferase III (GnT-III) gene. Transplant Proc 29:891-892.
500. Tanemura M, Miyagawa S, Ihara Y, Nishikawa A, Suzuki M, Yamamura K, Matsuda H, Shirakura R and Taniguchi N (1997b) Suppression of the xenoantigen GALα(1,3)Gal by N-acetylglucosaminyltransferase III (GnT-III) in transgenic mice. Transplant Proc 29:895-896.
501. Taylor RP and Ferguson PJ (1995) Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. J Hematother 4:357-362.
502. Taylor RP, Martin EN, Reinagel ML, Nardin A, Craig M, Choice Q, Schlimgen R. Greenbaum S, Incardona NL and Ochs HD (1997a) Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol 159:4035-4044.
503. Taylor RP, Reist CJ, Sutherland WM, Otto A, Labuguen RH and Wright EL (1992) In vivo binding and clearance of circulating antigen by bispecific heteropolymermediated binding to primate erythrocyte complement receptor. J Immunol 148: 2462-2468.
504. Taylor RP, Sutherland WM, Martin EN, Ferguson PJ, Reinagel ML, Gilbert E. Lopez K. Incardona NL and Ochs HD (1997b) Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J Immunol 158:842-850.
505. Taylor RP, Sutherland WM, Reist CJ, Webb DJ, Wright EL and Labuguen RH (1991) Use of heteropolymenc monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment. Proc Natl Acad Sci USA 88:3305-3309.
506. te Velthuia H, Jansen PG, Hack CE. Eijsman L and Wildevuur CR (1996) Specific complement inhibition with hepann-coated eztracorporeal circuits. Ann Theme Surg 91:1153-1157.
507. Tedder TF, Steeber DA, Chen A and Engel P (1995) The selecting. Vascular adhesion molecules. FASEB J 9:866-873.
508. Thomas TC, Rolling SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP and Evans MJ (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33:1389-1401
509. Till GO, Johnson KJ, Kunkel R and Ward PA (1982) Intravascular activation of complement and acute lung injury: Dependence on neutrophils and toxic oxygen metabolites J Clin Invest 69:1126-1135
510. Tojo SJ, Yokota S, Koike H, Schultz J, Hamazume Y, Misugi E, Yamada K, Hayashi M, Paulson JC and Morooka S (1996) Reduction of rat myocardial ischemia and reperfusion injury by gialyl Lewis x oligosaccharide and anti-rat P-selectin antibodies. Glycobiology 6:463-469.
511. Troepha A, Kizer JS and Chaiken IM (1992) Making sense from antisense: A review of experimental data and developing ideas on Bense-antisense peptide recognition. J Mol Recognit 5:43-54.
512. Tschopp J, Chonn A, Hertig S and French LE (1993) Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta and the b domain of C9. J Immunol 151:2159-2165.
513. Tschopp J, Müller-Eberhard HJ and Podack ER (1982) Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature 298:534-538.
514. Tschopp J, Maason D, Schäfer S, Peitsch M and Preissner KT (1988) The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8 and C9 and perforin from cytolytic T-cells and inhibits their lytic activities. Biochemistry 27:4103-4109
515. Tsuji RF, Magae J, Nagai K and Yamasaki M (1992a) Effects of L-156,602, a C5a receptor antagonist, on mouse experimental models of inflammation. Biosci Biotechnol Biochem 56:2034-2036.
516. Tsuji RF, Uramoto M, Koshino H, Tsuji NM, Magae J, Nagai K and Yamasaki M (1992b) Preferential suppression of delayed-type hypersensitivity by L-156,602, a C5a receptor antagonist. Biosci Biotechnol Biochem 86:1686-1689.
517. van den Berg RH, Faber-Krol M, van Es LA and Dana MR (1995) Regulation of the function of the first component of complement by human Clq receptor. Eur J Immunol 25:2206-2210
518. van den Berg RH, Prins F, Faber-Krol MC, Lynch NJ, Schwaeble W, van Es LA and Dana MR (1997) Intracellular localization of the human receptor for the globular domains of Clq. J Immunol 158:3909-3916.
519. van Oostrum J, van Heeke G and Schmilz A (1996) C5a receptor antagonists having substantially no agonist activity and methods for preparation. Patent WO 96/ 39503
520. Varki A (1994) Selectin ligands Proc Natl Acad Sci USA 91:7390-7397.
521. Varki A (1997) Selectin ligands: Will the real ones please stand up? J Clin Invest 99:158-162.
522. Vaughan HA, Oldenburg KR, Gallop MA, Atkin JD, McKenzie IFC and Sandrin MS (1996) Recognition of an octapeptide sequence by multiple Galo(1,3)Gal-binding proteins. Xenotransplantation 3:18-23.
523. Velazquez P, Cribbs DH, Poulos TL and Tenner AJ (1997) Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis. Nat Med 3:77-79.
524. Verlinde CLMJ and Hol WGJ (1994) Structure-based drug design: Progress, results and challenges. Structure 2:577-587.
525. Vogt W, Damerau B, von Zabern I, Nolte R and Brunahl D (1989) Non-enzymic activation of the fifth component of human complement, by oxygen radicals: Some properties of the activation product, C5b-like C5 Mol Immunol 26:1133-1142.
526. Vyse TJ, Morley BJ, Bartok I, Theodoridia EL, Davics KA, Webster AD and Walport MJ (1996) The molecular basis of hereditary complement factor I deficiency. J Clin Invest 97:925-933.
527. Walcheck B, Kahn J, Fisher JM, Wang BB, Fisk RS, Payan DG, Feehan C, Belagen R, Darlak K, Spatola AF and Kishimoto TK (1996) Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. Nature 380:720-723.
528. Waldmann TA (1991) Monoclonal antibodies in diagnosis and therapy. Science 252:1657-1662.
529. Wang M-W, Johnston PS, Wright LJ, Lim SML and White DJG (1992) Immunofluorescent localization of pig complement component 3, regardless of the presence or absence of detectable immunoglobulins, in hyperacutely rejected heart xenografts. Histochem J 24:102-109
530. 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5 Proc Natl Acad Sci USA 93:8563-8568.
531. Wang Y, Rollins SA, Madri JA and Matis LA (1995) Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 92:8955-8959.
532. Ward PA (1995) Adhesion molecule knockouts: One step forward and one step backward. J Clin Invest 95:1425
533. Ward PA (1996) Role of complement in lung inflammatory injury Am J Pathol 149:1081-1086
534. Ward PA (1997) Recruitment of inflammatory cells into lung: Roles of cytokines, adhesion molecules and complement. J Lab Clin Med 129:400-404.
535. Ward PA and Till GO (1990) Pathophysiologic events related to thermal injury of skin. J Trauma 30:S75-S79.
536. Washburn RG, DeHart DJ, Agwu DE, Bryant-Varela BJ and Julian NC (1990) Aspergillus fumigatus complement inhibitor: Production, characterization and purification by hydrophobic interaction and thin-layer chromatography. Infect Immun 58:3508-3515.
537. Webster S, Bradt B, Rogers J and Cooper N (1997) Aggregation state-dependent activation of the classical complement pathway by the amyloid β peptide. J .Veurochem 69:388-398
538. Weiler JM, Daha MR, Austen KF and Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 73:3268-3272.
539. Weiler JM, Edens RE, Linhardt RJ and Kapelanski DP (1992) Heparin and modified heparin inhibit complement activation in vivo. J Immunol 148:3210-3215
540. Weiler JM, Yurt RW, Fearon DT and Austen KF (1978) Modulation of the formation of the amplification convertase of complement, C3b,Bb, by native and commercial heparin. J Exp Med 147:409-421.
541. Weis JJ, Toothaker LE, Smith JA, Weis JH and Fearon DT (1988) Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med 167:1047-1066.
542. Weiser MR, Williams JP, Moore FD Jr., Kobzik L, Ma M, Hechtman HB and Carroll MC (1996) Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 183:2343-2348.
543. Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC Jr , Carson GR, Roux KH. Weisfeldt ML and Fearon DT (1990a) Recombinant soluble CR1 suppressed complement activation, inflammation and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 103:64-72.
544. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr , Carson GR, Concino MF, Boyle MP, Roui KH, Weisfeldt ML and Fearon DT (1990b) Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Sconce 249:146-151.
545. Wetael RA (1995) Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 7:48-53.
546. Wetsel RA and Kolb WP (1982) Complement-independent activation of the fifth component (C5) of human complement: Limited trypsin digestion resulting in the expression of biological activity. J Immunol 128:2209-2216.
547. Wetsel RA and Kolb WP (1983) Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med 157: 2029-2048.
548. Whaley K and Ruddy S (1976) Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inartivator. Science 193:1011-1013.
549. White D (1996) Alteration of complement activity: A strategy for xenotransplanta- tion. Trends Biotechnol 14:3-5
550. Winzler RJ (1973) The chemistry of glycoproteins, in Hormonal Proteins and Pep tides (Li CH, ed) Vol 1, pp 1-15, Academic Press, New York.
551. Wuillemin WA, te Velthuis H. Lubbers YTP, de Ruig CP, Eidering E and Hack CE (1997) Potentiation of Cl inhibitor by glycosaminoglycans: Dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 159:1953-1960.
552. Würzner R, Schulze M, Happe L, Franzke A, Bieber FA, Oppermann M and Götze O (1991) Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 8:328-340.
553. Yamada H, Kiyohara H, Cyong J-C and Otsuka Y (1987) Structural characterization of an anti-complementary arabinogalactan from the roots of Angelira acutiloba Kitagawa. Carbohydr Res 159:275-291.
554. Yamada H, Ra K-S. Kiyohara H, Cyong J-C, Yang HC and Otsuka Y (1988) Characterization of anti-complementary neutral poJysacchandes from the roots of Bupleurum falcatum. Phytochemistry 27:3163-3168.
555. Ye Y, Neethling FA, Niekrasz M, Koren E, Richards SV, Martin M, Kosanke S. Oriol R and Cooper DK (1994) Evidence that intravenously administered alphagalactosy) carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (HK15) and transplanted pig hearts Transplantation 58:330-337.
556. Yeh CG, Marsh HC Jr., Carson OR, Berman L, Concino MF, Scesney SM, Kuestner RE, Skibbens R, Donahue KA and Ip SH (1991) Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats. J Immunol 146:250-256
557. Yomtovian R, Prince GM and Medof ME (1993) The molecular basis for paroxysmal nocturnal hemoglobinuha. Transfusion 33:852-873.
558. Yu JH, Abagyan R, Dong SH. Gilbert A, Nussenzweig V and Tomlinson S (1997) Mapping the active site of CD59 J Exp Med 185:745-753.
559. a: A superior oligosaccharide hgand for human K-selectin. J Biol Chem 269:1595-1598
560. Zalman LS (1992) Homologous restriction factor. Curr Top Microbiol Immunol 178:87-100.
561. Zhang RL, Chopp M, Zhang ZG, Phillips ML, Rosenbloom CL, Cruz R and Manning A (1996) E-selectin in focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 16:1126-1136.
562. Zhang X, Boyar W, Galakatos N and Gonnella NC (1997) Solution structure of a unique C5a semi-synthetic antagonist: Implications in receptor binding. Protein Sci 6:65-72.
563. Zhao J-F, Kiyohara H, Yamada H, Takemoto N and Kawamura H (1991) Heterogeneity and characterization of mitogenic and anticomplemenlary pectic polysaccharidea from the roots of Glycyrrhiza uralensis Fisch et D.C. Carbohydr Res 219: 149-172.
564. Zhou QS, Zhao J, Husler T and Sims PJ (1996) Expression of recombinant CD59 with an N-terminal peptide epitope facilitates analysis of residues contributing to its complement-inhibitory function. Mol Immunol 33:1127-1134.
565. Ziccardi RJ and Cooper NR (1979) Active disassembly of the first complement component, C1, by C1 inactivator. J Immunol 123:788-792.
566. Zilow G, Joka T, Obertacke U, Rother U and Kirschfink M (1992) Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome. Crit Care Med 20:468-473.
567. Zimmerman GA, Prescott SM and McIntyre TM (1992) Endothelial cell interactions with granulocytes: Tethering and signalling molecules. Immunol Today 13:93-100.